Pharmacological treatment: how to choose your drug (if any)
19 March 2022
Open Access
A curated selection of highlights
24 October 2021
ESC Premium Access
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage